Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Apr 3, 2009

NEW YORK (GenomeWeb News) - Qiang Zhang has been named director of the Hamner Center for Dose Response Modeling at the Hamner Institutes for Health Sciences. In this position, Zhang will lead the center's systems biology efforts to understand non-linear biological response networks and to develop computational methodologies for understanding cellular pathways and toxic response.

Zhang was a post-doctoral researcher at the Hamner Institute for Health Sciences from 2003 to 2006, and after that he was promoted to research investigator.


Christopher Ahlberg has joined Fina Technologies' board of directors. Ahlberg, a founder and former CEO of Spotfire, also serves on the board of directors at Apptus Technologies AB and the Hult International Business School. He also was executive VP of Tibco and president of Tibco's Spotfire division.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail edi[email protected] to appear in People in the News, a weekly roundup of industry comings and goings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.